Low-dose radioimmuno-therapy of cancer.
Four decades of genomic, cellular, animal and human data have shown that low-dose ionizing radiation stimulates positive genomic and cellular responses associated with effective cancer prevention and therapy and increased life span of mammals and humans.( 1-8) Nevertheless, this data is questioned because it seems to contradict the well demonstrated linear relation between ionizing radiation dose and damage to DNA without providing a clear mechanistic explanation of how low-dose radiation could produce such beneficial effects. This apparent contradiction is dispelled by current radiobiology that now includes DNA damage both from ionizing radiation and from endogenous metabolic free radicals, and coupled with the biological response to low-dose radiation. Acceptance of current radiobiology would invalidate long established recommendations and regulations of worldwide radiation safety organizations and so destroy the basis of the very expensive existing system of regulation and remediation. More importantly, current radiobiology would facilitate urgently needed clinical trials of low dose radiation (LDR) cancer therapy.
Pollycove
Myron
M
School of Medicine, University of California, San Francisco, San Francisco, CA, USA. pollycove@comcast.net
Feinendegen
Ludwig E
LE
D000222:Adaptation, Physiological / Q000528:radiation effects; D000818:Animals; D018849:Controlled Clinical Trials as Topic; D004247:DNA / Q000528:radiation effects; D004249:DNA Damage; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D007107:Immune System / Q000528:radiation effects; D051379:Mice; D009369:Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D051381:Rats; D015996:Survival Rate
D004247:DNA